The emphasis of this report is the awareness of clinicians and pharmacotherapists about these interactions.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Palmoplantar Erythrodysesthesia Syndrome (PPES) caused by chemotherapeutic agents is rarely life threatening and requires a reduction in dose or discontinuation of chemotherapy.
📊
Key Findings & Data:In this combination, voriconazole probably inhibits the P-glycoprotein pump, which leads to an increase in the cytarabine concentration.
💡
Conclusion & Impact:The emphasis of this report is the awareness of clinicians and pharmacotherapists about these interactions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Palmoplantar Erythrodysesthesia Syndrome (PPES) caused by chemotherapeutic agents is rarely life threatening and requires a reduction in dose or discontinuation of chemotherapy. The use of cytarabine and doxorubicin in the treatment of acute myeloid leukemia (AML) along with voriconazole can potentially alter the metabolism of the drugs and cause some interactions. In this study, we presented a case of AML who received cytarabine and doxorubicin as a chemotherapy regimen and voriconazole as a prophylactic anti-fungal. In this combination, voriconazole probably inhibits the P-glycoprotein pump, which leads to an increase in the cytarabine concentration. The emphasis of this report is the awareness of clinicians and pharmacotherapists about these interactions.
🔖
Cite This Article
ARDAKANI, M. T., HAGHIGHI, S., SHOKOUHI, S., NAEINI, B. A., MEIDANI, M., HASSANPOUR, R., SAFFAEI, A. (2022). Cytarabine and Doxorubicin-Induced Palmoplantar Erythrodysesthesia Syndrome: The Possible Role of Voriconazole Interaction. Eurasian Journal of Medicine, Cilt: 51 - Sayı: 3, 313–315. https://ajindex.com/articles/508916
Miller KK, Gorcey L, McLellan BN. Chemotherapy- induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 2014
[CrossRef] 2. Mangili G, Petrone M, Gentile C, De Marzi P, Viganò R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling. Gynecol Oncol 2008
[CrossRef] 3. Choi SJ, Shin SC, Choi JS. Effects of myricetin on the bioavailability of doxorubicin for oral drug delivery in rats: possible role of CYP3A4 and Pglycoprotein inhibition by myricetin. Arch Pharm Res 2011
[CrossRef] 4. Tavakoli-Ardakani M, Eshraghi A, Hajhossein Talasaz A, Salamzadeh J. A Drug Utilization Evaluation Study of Amphotericin B in Neutropenic Patients in a Teaching Hospital in Iran. IJPR. 2012
Nivoix Y, Ubeaud-Sequier G, Engel P, Leveque D, Herbrecht R. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 2009
[CrossRef] 6. Colburn DE, Giles FJ, Oladovich D, Smith JA. In vitro evaluation of cytochrome P450- mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 2004
[CrossRef] 7. Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999
Alzghari SK, Seago SE, Cable CT, Herrington JD. Severe palmar-plantar erythrodysesthesia and aplasia in an adult undergoing re-induction treatment with high-dose cytarabine for acute myelogenous leukemia: a possible drug interaction between posaconazole and cytarabine. J Oncol Pharm Pract 2017
[CrossRef] 9. Sakurada H, Aoi M, Yuge M, et al. A Case of a Multidisciplinary Team Approach to Serious Hand-Foot Syndrome Induced by High-Dose Cytarabine Therapy. Gan To Kagaku Ryoho 2016
Sharma A, Baghmar S. Hand foot syndrome associated with standard dose cytarabine. Indian J Med Paediatr Oncol 2013